VialOwlLibrary / Skin and hair
Argireline
Also known as Acetyl hexapeptide-8, Acetyl hexapeptide-3
Human trials
Synthetic hexapeptide used in topical cosmetics, designed to reduce the muscle signalling that forms expression lines. Evidence is from small cosmetic studies; skin penetration is limited.
Not an approved medicine. Argireline is not an approved medicine for this use in Australia or the United States. This page summarises published research for information only. It is not a recommendation to use Argireline, and VialOwl does not sell or supply it.
Background
A synthetic six amino acid peptide (acetyl hexapeptide-8, sequence Ac-EEMQRR-NH2) designed by researchers at Miguel Hernández University in Spain and published in 2002 as a milder, topical alternative to botulinum toxin for expression lines.
How it is thought to work
It mimics part of the SNAP-25 protein and in lab tests interferes with the SNARE complex that nerve endings use to release signalling chemicals, which could weaken the muscle contractions behind expression lines. Because it is large and water loving, how much reaches the nerve endings through intact skin is uncertain.
What is claimed, and the evidence
| Claim | Evidence | Notes |
|---|---|---|
| Reducing expression lines and wrinkle depth | Small human studies | Small cosmetic studies: up to 30% reduction in wrinkle depth over 30 days in the original 2002 study, and a 60 person placebo controlled study in China (2013). Independent, large trials are lacking. |
| Skin elasticity and hydration | Small human studies | Reported in some cosmetic studies; skin penetration is limited. |
| 'Botox in a jar' results | No published evidence | Marketing claim; it is far less potent than botulinum toxin and its ability to reach facial muscles is unproven. |
Side effects
| Effect | How often | Notes |
|---|---|---|
| Skin irritation | Frequency unknown | The original study reported no primary irritation at high concentrations; large safety studies are lacking. |
| Systemic side effects | Frequency unknown | None described in the published cosmetic studies; it is used topically and absorption appears low. |
Warnings
- It is a cosmetic ingredient, not a medicine, and is not intended to be injected.
- Products sold as injectable 'Argireline' are unapproved and unregulated; purity and sterility are unknown.
Regulatory status
- Australia
- Cosmetic ingredient. Not included on the ARTG as a medicine and not listed in the Poisons Standard (June 2026).
- United States
- Cosmetic ingredient; not an FDA approved drug.
Sources
- Blanes-Mira et al. 2002, A synthetic hexapeptide (Argireline) with antiwrinkle activity (PubMed)
- Zdrada-Nowak et al. 2025, Acetyl hexapeptide-8 in cosmeceuticals: skin permeability and efficacy (PubMed)
- Wang et al. 2013, Anti wrinkle efficacy of Argireline in Chinese subjects (PubMed)
Also in Skin and hair
From the VialOwl library, reviewed 26 September 2026. For education and general information. It is not medical advice and not a recommendation to use Argireline.